drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous T cells engineered with a CD19-specific chimeric antigen receptor to target and eliminate CD19+ B cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically modified to express a chimeric antigen receptor that binds CD19 on B cells. CAR engagement delivers CD3-zeta and costimulatory signals that activate the T cells to proliferate, release cytokines, and kill CD19-positive malignant B cells, resulting in targeted depletion of pathogenic B-cell populations.
drug_name
CD19-directed CAR T-cell therapy
nct_id_drug_ref
NCT06387121